The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases

Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabet...

Descripción completa

Detalles Bibliográficos
Autor principal: Butrous, Ghazwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bloomsbury Qatar Foundation Journals 2014
Materias:
Mechanisms of Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352681/
https://www.ncbi.nlm.nih.gov/pubmed/25780785
http://dx.doi.org/10.5339/gcsp.2014.42
_version_ 1782360497165697024
author Butrous, Ghazwan
author_facet Butrous, Ghazwan
author_sort Butrous, Ghazwan
collection PubMed
description Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.
format Online
Article
Text
id pubmed-4352681
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bloomsbury Qatar Foundation Journals
record_format MEDLINE/PubMed
spelling pubmed-43526812015-03-16 The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Butrous, Ghazwan Glob Cardiol Sci Pract Mechanisms of Disease Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases. Bloomsbury Qatar Foundation Journals 2014-10-16 /pmc/articles/PMC4352681/ /pubmed/25780785 http://dx.doi.org/10.5339/gcsp.2014.42 Text en © 2014 Butrous, licensee Bloomsbury Qatar Foundation Journals. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mechanisms of Disease
Butrous, Ghazwan
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
title The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
title_full The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
title_fullStr The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
title_full_unstemmed The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
title_short The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
title_sort role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
topic Mechanisms of Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352681/
https://www.ncbi.nlm.nih.gov/pubmed/25780785
http://dx.doi.org/10.5339/gcsp.2014.42
work_keys_str_mv AT butrousghazwan theroleofphosphodiesteraseinhibitorsinthemanagementofpulmonaryvasculardiseases
AT butrousghazwan roleofphosphodiesteraseinhibitorsinthemanagementofpulmonaryvasculardiseases

Ejemplares similares